Boehringer Ingelheim has reported positive topline results from the phase III SYNCHRONIZE‑1 trial, showing that its ...

A UK biotech company has launched what it describes as a world‑first platform of lab‑grown human muscle designed to give drug ...

Subcutaneous pembrolizumab has now been administered to the first patients in the UK following its nationwide rollout across NHS hospitals, offering a significantly faster alternative to intravenous ...

BioDuro has entered a strategic partnership with CTI Biotechnology to build an integrated preclinical development platform ...

David Apelian, CEO of Theolytics, said: “We are proud to announce the dosing of the first patient in this important study.” ...

The UK’s Medicines & Healthcare Products Regulatory Agency has granted marketing authorisation to Enflonsia (clesrovimab), ...

AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, ...

Kahimmune Therapeutics has signed a scientific collaboration agreement with Gustave Roussy to support the selection and ...

This month’s curiously different PharmaTimes explores exciting new ecosystems across the life sciences. We examine the rise ...